Screener
BioMarin Pharmaceuticals BMRN Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $44.76M-81.4% | $105.53M-43.2% | —— | -$30.74M-129% | $240.53M+124% | ||
| $97.64M+426% | $16.41M-25.6% | $20.44M-13.4% | $18.49M-2.7% | $18.56M-29.9% | ||
| $75.69M+59.3% | $43.46M+15.3% | $46.91M-9.6% | $49.27M+13.3% | $47.53M-0.8% | ||
| $168.11M-9.3% | $220.65M+26.5% | $99.64M-46.3% | $368.69M+66.5% | $185.27M+56.0% | ||
| $28.82M+68.5% | $20.92M+24.8% | $40.72M+109% | $28.45M+54.1% | $17.1M-19.8% | ||
| -$5.1B-40,417% | $725.53M+2,669% | -$42.45M-156% | -$330.96M— | -$12.59M-114% | ||
| $2.8B— | $850M— | —— | —— | $0— | ||
| $2.74B+59,591% | $813.17M+2,197% | $0— | -$2.17M+99.6% | -$4.6M— | ||
| -$2.2B-1,432% | $1.76B+1,562% | $61.57M-77.0% | $36.29M+112% | $165.01M-26.7% | ||
| $139.29M-17.2% | $199.73M+26.7% | $58.92M-64.5% | $340.24M+67.6% | $168.17M+72.6% |
FAQ
- How much cash does BioMarin Pharmaceuticals generate?
- BioMarin Pharmaceuticals (BMRN) generated $857.1M in operating cash flow over the trailing twelve months.
- What is BioMarin Pharmaceuticals's free cash flow?
- After $118.9M of capital expenditures, BioMarin Pharmaceuticals's free cash flow was $738.2M over the trailing twelve months, up 6.2% year over year.
- Where does BioMarin Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
